The overgrowth syndromes are important to diagnose, not just for accurate genetic counseling, but also for knowledge surrounding cancer surveillance and prognosis. There has been a recent expansion in the number of genes associated with a mendelian overgrowth phenotype, so this review updates previous classifications of overgrowth syndromes. We also describe a clinical and molecular approach to the investigation of individuals presenting with overgrowth. This review aims to assist the clinical diagnosis of generalized overgrowth syndromes by outlining the salient features of well-known overgrowth syndromes alongside the many syndromes that have been discovered and classified more recently. We provide key clinical “handles” to aid clinical diagnosis and a list of genes to aid with panel design when using next generation sequencing, which we believe is frequently needed due to the overlapping phenotypic features seen between overgrowth syndromes.

Keywords:
Large stature, Macrocephaly, Macrosomia, Obesity, Overgrowth, Tall stature
1.
Aggarwal S, Bhowmik AD, Ramprasad VL, Murugan S, Dalal A: A splice site mutation in HERC1 leads to syndromic intellectual disability with macrocephaly and facial dysmorphism: further delineation of the phenotypic spectrum. Am J Med Genet A 170:1868-1873 (2016).
2.
Akawi N, Ben-Salem S, Lahti L, Partanen J, Ali BR, Al-Gazali L: A recessive syndrome of intellectual disability, moderate overgrowth, and renal dysplasia predisposing to Wilms tumor is caused by a mutation in FIBP gene. Am J Med Genet A 170:2111-2118 (2016).
3.
Argente J, Sotos JF: Overgrowth with and without obesity: clinical and molecular principles (in Spanish). An Pediatr (Barc) 76:161.e1-128 (2012).
4.
Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, et al: Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet 44:277-284 (2012).
5.
Babbs C, Lloyd D, Pagnamenta AT, Twigg SR, Green J, et al: De novo and rare inherited mutations implicate the transcriptional coregulator TCF20/SPBP in autism spectrum disorder. J Med Genet 51:737-747 (2014).
6.
Basel-Vanagaite L: Acute lymphoblastic leukemia in Weaver syndrome. Am J Med Genet A 152A:383-386 (2010).
7.
Baujat G, Rio M, Rossignol S, Sanlaville D, Lyonnet S, et al: Clinical and molecular overlap in overgrowth syndromes. Am J Med Genet C Semin Med Genet 137C:4-11 (2005).
8.
Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, et al: Disruptive CHD8 mutations define a subtype of autism early in development. Cell 158:263-276 (2014).
9.
Biesecker L: The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet 14:1151-1157 (2006).
10.
Cecconi M, Forzano F, Milani D, Cavani S, Baldo C, et al: Mutation analysis of the NSD1 gene in a group of 59 patients with congenital overgrowth. Am J Med Genet A 134:247-253 (2005).
11.
Choufani S, Shuman C, Weksberg R: Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 154C:343-354 (2010).
12.
Choufani S, Cytrynbaum C, Chung BH, Turinsky AL, Grafodatskaya D, et al: NSD1 mutations generate a genome-wide DNA methylation signature. Nat Commun 6:10207 (2015).
13.
Cohen AS, Gibson WT: EED-associated overgrowth in a second male patient. J Hum Genet 61:831-834 (2016).
14.
Cohen AS, Tuysuz B, Shen Y, Bhalla SK, Jones SJ, Gibson WT: A novel mutation in EED associated with overgrowth. J Hum Genet 60:339-342 (2015).
15.
Cohen MM Jr: Perspectives on overgrowth syndromes. Am J Med Genet 79:234-237 (1998).
16.
Cooney E, Bi W, Schlesinger AE, Vinson S, Potocki L: Novel EED mutation in patient with Weaver syndrome. Am J Med Genet A 173:541-545 (2017).
17.
Cordeddu V, Redeker B, Stellacci E, Jongejan A, Fragale A, et al: Mutations in ZBTB20 cause Primrose syndrome. Nat Genet 46:815-817 (2014).
18.
Cottereau E, Mortemousque I, Moizard MP, Bürglen L, Lacombe D, et al: Phenotypic spectrum of Simpson-Golabi-Behmel syndrome in a series of 42 cases with a mutation in GPC3 and review of the literature. Am J Med Genet C Semin Med Genet 163C:92-105 (2013).
19.
Cowan R, Hoban P, Kelsey A, Birch JM, Gattamaneni R, Evans DG: The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 76:141-145 (1997).
20.
Di Donato N, Riess A, Hackmann K, Rump A, Huebner A, et al: Macrocephaly, obesity, mental (intellectual) disability, and ocular abnormalities: alternative definition and further delineation of MOMO syndrome. Am J Med Genet A 158A:2857-2862 (2012).
21.
Dolan M, Mendelsohn NJ, Pierpont ME, Schimmenti LA, Berry SA, Hirsch B: A novel microdeletion/microduplication syndrome of 19p13.13. Genet Med 12:503-511 (2010).
22.
Douglas J, Tatton-Brown K, Coleman K, Guerrero S, Berg J, et al: Partial NSD1 deletions cause 5% of Sotos syndrome and are readily identifiable by multiplex ligation dependent probe amplification. J Med Genet 42:e56 (2005).
23.
Douglas J, Cilliers D, Coleman K, Tatton-Brown K, Barker K, et al: Mutations in RNF135, a gene within the NF1 microdeletion region, cause phenotypic abnormalities including overgrowth. Nat Genet 39:963-965 (2007).
24.
Durand C, Rappold GA: Height matters-from monogenic disorders to normal variation. Nat Rev Endocrinol 9:171-177 (2013).
25.
Fickie MR, Lapunzina P, Gentile JK, Tolkoff-Rubin N, Kroshinsky D, et al: Adults with Sotos syndrome: review of 21 adults with molecularly confirmed NSD1 alterations, including a detailed case report of the oldest person. Am J Med Genet A 155A:2105-2111 (2011).
26.
Field M, Tarpey PS, Smith R, Edkins S, O'Meara S, et al: Mutations in the BRWD3 gene cause X-linked mental retardation associated with macrocephaly. Am J Hum Genet 81:367-374 (2007).
27.
Friedman JM: Neurofibromatosis 1, in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, et al (eds): GeneReviews® [Internet] (University of Washington, Seattle 1993-2017). Initial posting: Oct 2, 1998; last update: Nov 2, 2017.
28.
Gibson WT, Hood RL, Zhan SH, Bulman DE, Fejes AP, et al: Mutations in EZH2 cause Weaver syndrome. Am J Hum Genet 90:110-118 (2012).
29.
Gilissen C, Hoischen A, Brunner HG, Veltman JA: Disease gene identification strategies for exome sequencing. Eur J Hum Genet 20:490-497 (2012).
30.
Glaser B: Familial hyperinsulinism, in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, et al (eds): GeneReviews® [Internet] (University of Washington, Seattle 1993-2017). Initial posting: Aug 19, 2003; last update: Jan 24, 2013.
31.
Gorlin RJ: Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med 6:530-539 (2004).
32.
Greer KJ, Kirkpatrick SJ, Weksberg R, Pauli RM: Beckwith-Wiedemann syndrome in adults: observations from one family and recommendations for care. Am J Med Genet A 146A:1707-1712 (2008).
33.
Gripp KW, Lin AE: Costello syndrome, in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, et al (eds): GeneReviews® [Internet] (University of Washington, Seattle 1993-2017). Initial posting: Aug 29, 2006; last update: Jan 12, 2012.
34.
Gripp KW, Baker L, Kandula V, Conard K, Scavina M, et al: Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation. Am J Med Genet A 170:2559-2569 (2016).
35.
Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, et al: Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 44:783-787 (2012).
36.
Hirai N, Matsune K, Ohashi H: Craniofacial and oral features of Sotos syndrome: differences in patients with submicroscopic deletion and mutation of NSD1 gene. Am J Med Genet A 155A:2933-2939 (2011).
37.
Houge G, Haesen D, Vissers LE, Mehta S, Parker MJ, et al: B56delta-related protein phosphatase 2A dysfunction identified in patients with intellectual disability. J Clin Invest 125:3051-3062 (2015).
38.
Imagawa E, Higashimoto K, Sakai Y, Numakura C, Okamoto N, et al: Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome. Hum Mutat 38:637-648 (2017).
39.
Kamien B, Digilio MC, Novelli A, O'Donnell S, Bain N, et al: Narrowing the critical region for overgrowth within 13q14.2-q14.3 microdeletions. Eur J Med Genet 58:629-633 (2015).
40.
Kannu P, Campos-Xavier AB, Hull D, Martinet D, Ballhausen D, Bonafé L: Post-axial polydactyly type A2, overgrowth and autistic traits associated with a chromosome 13q31.3 microduplication encompassing miR-17-92 and GPC5. Eur J Med Genet 56:452-457 (2013).
41.
Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K: Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrinol 168:557-564 (2013).
42.
Klaassens M, Morrogh D, Rosser EM, Jaffer F, Vreeburg M, et al: Malan syndrome: Sotos-like overgrowth with de novo NFIX sequence variants and deletions in six new patients and a review of the literature. Eur J Hum Genet 23:610-615 (2015).
43.
Kosaki R, Fujita H, Ueoka K, Torii C, Kosaki K: Overgrowth of prenatal onset associated with submicroscopic 9q22.3 deletion. Am J Med Genet A 155A:903-905 (2011).
44.
Kosaki R, Terashima H, Kubota M, Kosaki K: Acute myeloid leukemia-associated DNMT3A p.Arg882His mutation in a patient with Tatton-Brown-Rahman overgrowth syndrome as a constitutional mutation. Am J Med Genet A 173:250-253 (2017).
45.
Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS: Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 157:83-89 (2011).
46.
Lachlan KL, Lucassen AM, Bunyan D, Temple IK: Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 44:579-585 (2007).
47.
Lapunzina P: Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am J Med Genet C Semin Med Genet 137:53-71 (2005).
48.
Li M, Shuman C, Fei YL, Cutiongco E, Bender HA, et al: GPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. Am J Med Genet 102:161-168 (2001).
49.
Longy M, Coulon V, Duboué B, David A, Larrègue M, et al: Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J Med Genet 35:886-889 (1998).
50.
Loveday C, Tatton-Brown K, Clarke M, Westwood I, Renwick A, et al: Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth. Hum Mol Genet 24:4775-4779 (2015).
51.
Lumish HS, Wynn J, Devinsky O, Chung WK: Brief Report: SETD2 mutation in a child with autism, intellectual disabilities and epilepsy. J Autism Dev Disord 45:3764-3770 (2015).
52.
Luscan A, Laurendeau I, Malan V, Francannet C, Odent S, et al: Mutations in SETD2 cause a novel overgrowth condition. J Med Genet 51:512-517 (2014).
53.
Maas SM, Vansenne F, Kadouch DJ, Ibrahim A, Bliek J, et al: Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. Am J Med Genet A 170:2248-2260 (2016).
54.
Malan V, Rajan D, Thomas S, Shaw AC, Louis Dit Picard H, et al: Distinct effects of allelic NFIX mutations on nonsense-mediated mRNA decay engender either a Sotos-like or a Marshall-Smith syndrome. Am J Hum Genet 87:189-198 (2010).
55.
Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, et al: Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16:333-334 (1997).
56.
Mattioli F, Piton A, Gérard B, Superti-Furga A, Mandel JL, Unger S: Novel de novo mutations in ZBTB20 in Primrose syndrome with congenital hypothyroidism. Am J Med Genet A 170:1626-1629 (2016).
57.
Minatogawa M, Takenouchi T, Tsuyusaki Y, Iwasaki F, Uehara T, et al: Expansion of the phenotype of Kosaki overgrowth syndrome. Am J Med Genet A 173:2422-2427 (2017).
58.
Molin AM, Andrieux J, Koolen DA, Malan V, Carella M, et al: A novel microdeletion syndrome at 3q13.31 characterised by developmental delay, postnatal overgrowth, hypoplastic male genitals, and characteristic facial features. J Med Genet 49:104-109 (2012).
59.
Moncla A, Missirian C, Cacciagli P, Balzamo E, Legeai-Mallet L, et al: A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype. Hum Mutat 28:1183-1188 (2007).
60.
Neri G, Gurrieri F, Zanni G, Lin A: Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 79:279-283 (1998).
61.
Neylon OM, Werther GA, Sabin MA: Overgrowth syndromes. Curr Opin Pediatr 24:505-511 (2012).
62.
Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C: Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 96:E2063-2071 (2011).
63.
Nguyen LS, Schneider T, Rio M, Moutton S, Siquier-Pernet K, et al: A nonsense variant in HERC1 is associated with intellectual disability, megalencephaly, thick corpus callosum and cerebellar atrophy. Eur J Hum Genet 24:455-458 (2016).
64.
Ornoy A: Prenatal origin of obesity and their complications: gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. Reprod Toxicol 32:205-212 (2011).
65.
Ortega-Recalde O, Beltrán OI, Gálvez JM, Palma-Montero A, Restrepo CM, et al: Biallelic HERC1 mutations in a syndromic form of overgrowth and intellectual disability. Clin Genet 88:e1-3 (2015).
66.
Partington MW, Fagan K, Soubjaki V, Turner G: Translocations involving 4p16.3 in three families: deletion causing the Pitt-Rogers-Danks syndrome and duplication resulting in a new overgrowth syndrome. J Med Genet 34:719-728 (1997).
67.
Phadke SR, Aggarwal S, Kumari N: The expanding spectrum of Elejalde syndrome: overlap with other disorders of overgrowth. Clin Dysmorphol 20:98-101 (2011).
68.
Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, et al: 22q13 deletion syndrome. Am J Med Genet 101:91-99 (2001).
69.
Revencu N, Boon LM, Mulliken JB, Enjolras O, Cordisco MR, et al: Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 29:959-965 (2008).
70.
Sabin MA, Werther GA, Kiess W: Genetics of obesity and overgrowth syndromes. Best Pract Res Clin Endocrinol Metab 25:207-220 (2011).
71.
Sakazume S, Okamoto N, Yamamoto T, Kurosawa K, Numabe H, et al: GPC3 mutations in seven patients with Simpson-Golabi-Behmel syndrome. Am J Med Genet A 143A:1703-1707 (2007).
72.
Sarasua SM, Dwivedi A, Boccuto L, Chen CF, Sharp JL, et al: 22q13.2q13.32 genomic regions associated with severity of speech delay, developmental delay, and physical features in Phelan-McDermid syndrome. Genet Med 16:318-328 (2014).
73.
Schäfgen J, Cremer K, Becker J, Wieland T, Zink AM, et al: De novo nonsense and frameshift variants of TCF20 in individuals with intellectual disability and postnatal overgrowth. Eur J Hum Genet 24:1739-1745 (2016).
74.
Scurr I, Wilson L, Lees M, Robertson S, Kirk E, et al: Cantu syndrome: report of nine new cases and expansion of the clinical phenotype. Am J Med Genet A 155A:508-518 (2011).
75.
Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, et al: Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 44:481-484 (2007).
76.
Soorya L, Kolevzon A, Zweifach J, Lim T, Dobry Y, et al: Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism 4:18 (2013).
77.
Sotos JF, Argente J: Overgrowth disorders associated with tall stature. Adv Pediatr 55:213-254 (2008).
78.
Takenouchi T, Yamaguchi Y, Tanikawa A, Kosaki R, Okano H, Kosaki K: Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation. J Pediatr 166:483-486 (2015).
79.
Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C: Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400-407 (2012).
80.
Tatton-Brown K, Rahman N: Clinical features of NSD1-positive Sotos syndrome. Clin Dysmorphol 13:199-204 (2004).
81.
Tatton-Brown K, Rahman N: Sotos syndrome. Eur J Hum Genet 15:264-271 (2007).
82.
Tatton-Brown K, Rahman N: The NSD1 and EZH2 overgrowth genes, similarities and differences. Am J Med Genet C Semin Med Genet 163C:86-91 (2013).
83.
Tatton-Brown K, Weksberg R: Molecular mechanisms of childhood overgrowth. Am J Med Genet C Semin Med Genet 163C:71-75 (2013).
84.
Tatton-Brown K, Douglas J, Coleman K, Baujat G, Cole TR, et al: Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. Am J Hum Genet 77:193-204 (2005).
85.
Tatton-Brown K, Pilz DT, Orstavik KH, Patton M, Barber JC, et al: 15q overgrowth syndrome: a newly recognized phenotype associated with overgrowth, learning difficulties, characteristic facial appearance, renal anomalies and increased dosage of distal chromosome 15q. Am J Med Genet A 149A:147-154 (2009).
86.
Tatton-Brown K, Hanks S, Ruark E, Zachariou A, Duarte Sdel V, et al: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget 2:1127-1133 (2011).
87.
Tatton-Brown K, Murray A, Hanks S, Douglas J, Armstrong R, et al: Weaver syndrome and EZH2 mutations: clarifying the clinical phenotype. Am J Med Genet A 161A:2972-2980 (2013).
88.
Tatton-Brown K, Seal S, Ruark E, Harmer J, Ramsay E, et al: Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nat Genet 46:385-388 (2014).
89.
Tatton-Brown K, Cole TRP, Rahman N: Sotos syndrome, in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, et al (eds): GeneReviews® [Internet] (University of Washington, Seattle 1993-2017). Initial posting: Dec 17, 2004; last update: Nov 19, 2015 (2017a).
90.
Tatton-Brown K, Loveday C, Yost S, Clarke M, Ramsay E, et al: Mutations in epigenetic regulation genes are a major cause of overgrowth with intellectual disability. Am J Hum Genet 100:725-736 (2017b).
91.
Tenorio J, Mansilla A, Valencia M, Martínez-Glez V, Romanelli V, et al: A new overgrowth syndrome is due to mutations in RNF125. Hum Mutat 35:1436-1441 (2014).
92.
Thauvin-Robinet C, Duplomb-Jego L, Limoge F, Picot D, Masurel A, et al: Homozygous FIBP nonsense variant responsible of syndromic overgrowth, with overgrowth, macrocephaly, retinal coloboma and learning disabilities. Clin Genet 89:e1-4 (2016).
93.
Tlemsani C, Luscan A, Leulliot N, Bieth E, Afenjar A, et al: SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort. J Med Genet jmedgenet-2015-103638 (2016).
94.
Tosca L, Brisset S, Petit FM, Metay C, Latour S, et al: Genotype-phenotype correlation in 13q13.3-q21.3 deletion. Eur J Med Genet 54:e489-494 (2011).
95.
Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, et al: Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 371:2363-2374 (2014).
96.
van Bon BW, Gilissen C, Grange DK, Hennekam RC, Kayserili H, et al: Cantú syndrome is caused by mutations in ABCC9. Am J Hum Genet 90:1094-1101 (2012).
97.
Verge CF, Mowat D: Overgrowth. Arch Dis Child 95:458-463 (2010).
98.
Visser R, Koelma N, Vijfhuizen L, van der Wielen MJ, Kant SG, et al: RNF135 mutations are not present in patients with Sotos syndrome-like features. Am J Med Genet A 149A:806-808 (2009).
99.
Vu PY, Toutain J, Cappellen D, Delrue MA, Daoud H, et al: A homozygous balanced reciprocal translocation suggests LINC00237 as a candidate gene for MOMO (macrosomia, obesity, macrocephaly, and ocular abnormalities) syndrome. Am J Med Genet A 158A:2849-2856 (2012).
100.
Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK, Tainsky MA: Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. Am J Med Genet A 158A:3061-3064 (2012).
101.
Watson J, Depasquale K, Ghaderi M, Zwillenberg S: Nevoid basal cell carcinoma syndrome and fetal rhabdomyoma: a case study. Ear Nose Throat J 83:716-718 (2004).
102.
Wilkens A, Liu H, Park K, Campbell LB, Jackson M, et al: Novel clinical manifestations in Pallister-Killian syndrome: comprehensive evaluation of 59 affected individuals and review of previously reported cases. Am J Med Genet A 158A:3002-3017 (2012).
103.
Williams CA, Dagli A, Battaglia A: Genetic disorders associated with macrocephaly. Am J Med Genet A 146A:2023-2037 (2008).
104.
Yoneda Y, Saitsu H, Touyama M, Makita Y, Miyamoto A, et al: Missense mutations in the DNA-binding/dimerization domain of NFIX cause Sotos-like features. J Hum Genet 57:207-211 (2012).
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.